Click here for slides on this topic


LDL-C

Abbreviation for low-density lipoprotein cholesterol, the concentration of circulating cholesterol partitioned in low-density particles. LDL-C, also known as "bad cholesterol," has been shown to transport lipid from the blood to the tissues. High levels of LDL-C are considered a risk factor for developing coronary artery disease.
The following content matched the glossary term: LDL-C

Alirocumab Significantly Reduces LDL-C in High-Risk Patients in ODYSSEY FH I & FH II

Top

The PCSK9 inhibitor, alirocumab, significantly reduced LDL-C in high-risk patients with heterozygous FH in ODYSSEY FH I & FH II; from ESC 2015

NDEI.org Expert Commentary Silvio Inzucchi MD on IMPROVE-IT Subanalysis CV Benfits of Ezetimibe Exclusive to Subjects With Diabetes

Top

Silvio Inzucchi, MD, provides expert commentary on data from a subanalysis of IMPROVE-IT that showed the cardiovascular benefits of ezetimibe are restricted to patients with type 2 diabetes; from ESC Congress 2015.

CV Benefits of Ezetimibe Favor Patients With Type 2 Diabetes in IMPROVE-IT Analysis

Top

Data from a subanalysis of IMPROVE-IT at ESC Congress 2015 show that the cardiovascular benefits of ezetimibe are exclusive to individuals with type 2 diabetes. Includes expert commentary.

AHA ADA prevention of CVD in T2D - Cholesterol Management

Top

Summary of cholesterol management recommendations from the AHA ADA cardiovascular disease (CVD) prevention in type 2 diabetes guidelines.

AACE 2015 guidelines Cardiovascular Disease Management

Top

Summary of recommendations for managing cardiovascular disease (CVD), including dyslipidemia and hypertension, from the 2015 AACE diabetes guidelines 

AACE 2015 guidelines Diabetes Diagnosis

Top

Summary of recommendations for screening and diagnosing type 2 diabetes from the 2015 AACE guidelines. 

T195-04

Top

Patient education handout exploring the connection between diabetes and cardiovascular disease.

ADA 2016 Children & Adolescents

Top

Recommendations for treating and managing diabetes in children from the 2016 ADA guidelines

ADA 2016 Cardiovascular Disease (CVD) and Diabetes

Top

Recommendations for CVD management, including lipids and BP, in patients with type 2 diabetes from the 2016 ADA diabetes guidelines

ADA 2016 Glycemic Targets

Top

Glycemic targets and A1C for adults with diabetes from the 2016 ADA guidelines

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: LDL-C Slides Found: 131
Assessing Risk for Morbidity and Mortality: Comorbidities and Other Risk Factors
Effect of the Atkins Diet on Weight, Lipids, and Insulin
Low-Carbohydrate Diet vs Low-Fat Diet
Effect of Continuous and Intermittent Sibutramine on Lipids
Effect of Orlistat on Lipids and Glycemic Control in Patients
Association Between Small, Dense LDL and Insulin Resistance
ACP Guidelines on Management of Dyslipidemia in Type 2 Diabetes
Effect of 4 Diets on Weight Loss and Cardiac Risk Factors
Metabolic and Vascular Actions of PPAR-alpha and PPAR-gamma Agonists
GLAI: Enrollment Criteria
Non–HDL-C as a Predictor of Risk for CHD in Diabetes
Prevalence of IFG in Nondiabetic US Adolescents (Aged 12–19 Yrs)
Vildagliptin Is as Effective as Rosiglitazone in Lowering A1C but Without Weight Gain in Drug-Naïve Patients With T2D
SPARCL: Primary Outcome of Fatal or Nonfatal Stroke
SPARCL: First Events
TNT: Intensive Atorvastatin Treatment Reduces Cardiovascular Events in Patients With CHD and Diabetes
Inadequate Achievement of ADA Goals Among US Adults With Diabetes
Drug Nonadherence Is Associated With Adverse Clinical Outcomes in Diabetes
ADOPT: Adverse Events
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Lipids
GLAI: Comparison of TZDs on Lipoprotein Subclass Particle Size
Proportion of Diabetic Patients With Low HDL-C Stratified by Treatment, Sex, and Cardiovascular Disease
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
High-Normal A1C as a Type 2 Diabetes Predictor: Design
High-Normal A1C as a Type 2 Diabetes Predictor: Results
ORIGIN Omega-3 Fatty Acid Trial: Mean Change in Lipids
JUPITER: Design
JUPITER Analysis: Design
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Rationale
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Participant Profile
JUPITER: Study Design
JUPITER: Lipid and HsCRP Levels
JUPITER Results: Primary Endpoint
JUPITER Results: Components of Primary Endpoint
JUPITER Results: Summary
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Design
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Additional Parameters
Look AHEAD at 1 Year: Additional Results
RYGB Surgery: Long-Term Health-Related Outcomes Design
VADT Post-hoc Analysis: Satin Use and CAC Progression
Diabetic Retinopathy and Incident CV Events in ACCORD: Results
PREDIMED: Mediterranean Diet for Primary Prevention of CVD
HPS2-THRIVE: Niacin and Vascular Risk
HPS2-THRIVE: Niacin +Laropiprant for Vascular Risk Reduction
HPS2-THRIVE: LDL-Lowering Therapy Compliance
HPS2-THRIVE: Liver & Muscle-Related Adverse Events
AIM-HIGH: Niacin + Statin Therapy for Cardiovascular Risk Reduction
AIM-HIGH: Design
AIM-HIGH: Lipid Values at Baseline and 2 Years
CANTATA-D2: Effect of Canagliflozin Vs Sitagliptin on Lipid Values at 52 Weeks
CANTATA-M: Effect of Canagliflozin Vs Placebo on Lipid Values at 26 Weeks
ESH/ESC Hypertension Guidelines: Treatment of Risk Factors Associated With Hypertension
Look AHEAD: Lifestyle Changes Improve Glycemic Control, CV Risk Factors
Diabetes Surgery Study: Greater Number of Subjects Achieved Primary Endpoint with Gastric Bypass Vs Lifestyle & Medical Management
Diabetes Surgery Study: Design
Long-Term Obesity Medications: At Least 5% Weight Loss After 1 Year
ACC/AHA Cholesterol Guidelines 2013: Statin Benefit Groups for ASCVD Prevention
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 1: Secondary Prevention
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 1: Primary Prevention LDL-C 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 3: Primary Prevention Diabetes
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 4: Primary Prevention With 10-Yr ASCVD Risk 7.5% or Higher (No Diabetes)
ACC/AHA Cholesterol Guidelines 2013: High- and Moderate-Intensity Statin Therapy
ACC/AHA Cholesterol Guidelines 2013: The Argument Against LDL-C, Non-HDL-C Targets
ACC/AHA Cholesterol Guidelines 2013: Role of Biomarkers & Imaging Tests
ACC/AHA Cholesterol Guidelines 2013: LDL-C, Non-HDL-C Targets
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: LDL-C 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: Diabetes & LDL-C 70-189
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: LDL-C 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Secondary Prevention: Age 75 Years or Younger
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Secondary Prevention: Age 75 and Older
ACC/AHA Cholesterol Guidelines: Primary ASCVD Prevention for LDL-C 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Primary ASCVD Prevention: Age 40-75 With Diabetes or LDL 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Primary ASCVD Prevention: Age 40-75, LDL 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention in Individuals With 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention for Individuals Not in A Statin Benefit Group
ACC/AHA Cholesterol Guidelines 2013: 10-Yr ASCVD Risk Assessment Calculator: Primary Prevention
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Maximizing Statin Safety
ACC/AHA Cholesterol Guidelines 2013: Guidance on Nonstatin Therapies
ACC/AHA Cholesterol Guidelines 2013: Insufficient Response to Statin Therapy
AHA/ACC/TOS Obesity Guidelines: Weight Loss Outcomes in Overweight or Obese Adults
ACC/AHA Lifestyle Management Guidelines LDL-C | NDEI
ACC/AHA 2013 Lifestyle Management Guideline BP Lowering | NDEI
ACC/AHA Lifestyle Management Mediterranean Diet Lipids BP | NDEI
ACC/AHA Lifestyle Guidelines DASH Diet Lipids BP | NDEI
DASH Diet ACC/AHA 2013 Lifestyle Management Guidelines | NDEI
DASH Diet Lipids BP ACC AHA Lifestyle Management Guidelines | NDEI
ACC AHA Lifestyle Guidelines Saturated Fat Lipid Lowering | NDEI
ACC AHA Lifestyle Guidelines Trans Fat Cholesterol | NDEI
Physical Activity Blood Pressure Lipids ACC AHA Lifestyle Guideline | NDEI
ACC/AHA Cholesterol Guidelines 2013: Estimated 10-Yr ASCVD Risk Guides Statin Therapy
IDF Type 2 Diabetes Guidelines Cardiovascular Risk | NDEI
Canola Oil Diet Study Glycemia A1C Type 2 Diabetes | NDEI
Statin Potency & Type 2 Diabetes Risk | NDEI
Diabetes Macrovascular Complications US Adults 2012 | NDEI
SGLT2 Inhibitors Type 2 Diabetes Treatment Slides | NDEI
VA BEACH DIET Study: Impact of Diet on CVD Risk | NDEI
EMPA-REG Safety of Empagliflozin in Type 2 Diabetes & Hypertension SGLT2 | NDEI
CVD Treatment Statin ADA Type 1 Diabetes Guidelines | NDEI
AACE 2015 Diabetes Guidelines Cardiovascular Disease Targets | NDEI
AACE 2015 Guidelines Managing Dyslipidemia in Diabetes PPT | NDEI
AACE 2015 Diabetes Guidelines Dyslipidemia Treatment PPT | NDEI
Cholesterol Targets LDL Type 2 Diabetes AHA ADA Guidelines | NDEI
Combo Ezetimibe/Simvastatin LDL-C Type 2 Diabetes IMPROVE-IT | NDEI
Statin Therapy in Type 2 Diabetes ADA Guidelines 2016 | NDEI PPT
Statin Therapy Recommendations for Type 2 Diabetes ADA Guidelines | NDEI
JUPITER Secondary Analysis Assesses Statin Use & Diabetes Risk | NDEI
JUPITER High-Intensity Rosuvastatin & Lipoprotein Particles | NDEI
JUPITER Effect of High-Intensity Rosuvastatin on Lipoproteins Diabetes | NDEI
JUPITER Incident Diabetes Associated With More Risk Factors Rosuvastatin | NDEI
GAUSS-3 Evolocumab Reduces LDL-C in Statin-Intolerant Patients | NDEI
GAUSS-3 Absolute LDL-C Reduction With Evolocumab Statin Intolerance | NDEI
GAUSS-3: LDL-C Goal Achievement With Evolocumab Statin Intolerance | NDEI
GAUSS-3 Evolocumab Effects on Lipoproteins in Statin-Intolerant Patients | NDEI
GAUSS-3 Evolocumab Use in Statin-Intolerant Patients Muscle Symptoms | NDEI
GAUSS-3 Muscle-Related Adverse Events With Evolocumab & Ezetimibe | NDEI
GAUSS-3 Design Evolocumab Vs Ezetimibe in Statin Intolerance | NDEI
ACCELERATE Evacetrapib Doubles HDL-C & Lowers LDL-C CETP | NDEI
HOPE-3 LDL & Lipoprotein Reductions With Rosuvastatin Vs Placebo | NDEI
HOPE-3 Cholesterol- and BP-Lowering for Intermediate CV Risk Reduction | NDEI
HOPE-3 Lipid- & BP-Lowering Therapy for Primary Prevention PPT | NDEI
Lipoprotein Screening in Children & Adolescents NLA Cholesterol Guidelines | CCMD
Treating Dyslipidemia in Women NLA Cholesterol Guidelines | CCMD
Pharmacologic Therapy for Dyslipidemia in Women NLA Cholesterol Guidelines
NLA Cholesterol Guidelines LDL-C Treatment Targets | CCMD
NLA Cholesterol Guidelines Lipid Treatment Goals | CCMD
NLA Cholesterol Guidelines ASCVD Risk Factors Slides | CCMD PPT
Very-High ASCVD Risk LDL Goals NLA Cholesterol Guidelines | CCMD
LDL-C Target for High ASCVD Risk NLA Cholesterol Guidelines | CCMD
ASCVD Risk Assessment Algorithm NLA Cholesterol Guidelines | CCMD
Cholesterol Treatment Algorithm to Reduce ASCVD NLA Guidelines | CCMD
FH Treatment LDL-Apheresis NLA Cholesterol Guidelines PPT | CCMD